Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- 9 Meters Biopharma Inc (NASDAQ:NMTR) has collaborated with the European Biomedical Research Institute of Salerno, Italy (EBRIS) to study larazotide for multisystem inflammatory syndrome in children (MIS-C).
- Larazotide is a novel first-in-class tight junction regulator that the Company currently has in Phase 3 trial for adults with celiac disease.
- MIS-C is a severe and rare complication of COVID-19 with symptoms potentially including persistent fever, gastrointestinal symptoms, myocardial dysfunction, and cardiogenic shock with ventricular dysfunction in the setting of multisystem inflammation.
- EBRIS plans to initiate a Phase 2a study in MIS-C in Q4 2021.
- Under the terms of the collaboration agreement, 9 Meters will supply larazotide, and EBRIS will be responsible for conducting the Phase 2a trial inclusive of all associated clinical costs.
- Data readout is expected in 2022. Other financial terms of the transaction are undisclosed.
- Price Action: NMTR shares are up 0.48% at $1.04 during the market session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!